QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Julian who wrote (780)	12/9/1999 10:12:00 PM
From: Julian	Read Replies (1) of 1321

QLT issues correction to Nov. 17 Visudyne release QLT PhotoTherapeutics Inc QLT Shares issued 28,385,597 Dec 9 close $62.00 Thu 9 Dec 99 News Release Ms. Elayne Wandler reports A news release issued in Stockwatch on Nov. 17, 1999, by CIBA Vision, the eyecare unit of Novartis AG and QLT PhotoTherapeutics Inc., contained a typographical error incorrectly stating the Food & Drug Administration is expected to make a final decision regarding the approval of Visudyne therapy on or before Feb. 2, 2000. The correct date is Feb. 12, 2000. Under priority review status, the FDA is expected to complete their review of the Aug. 16 submission within 180 days; or, on or before Feb. 12, 2000. WARNING: The company relies upon litigation protection for "forward-looking" statements. (c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next